AU2001231137A1 - Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors - Google Patents
Treatment of neuropsychiatric disease with protease and neuraminidase inhibitorsInfo
- Publication number
- AU2001231137A1 AU2001231137A1 AU2001231137A AU3113701A AU2001231137A1 AU 2001231137 A1 AU2001231137 A1 AU 2001231137A1 AU 2001231137 A AU2001231137 A AU 2001231137A AU 3113701 A AU3113701 A AU 3113701A AU 2001231137 A1 AU2001231137 A1 AU 2001231137A1
- Authority
- AU
- Australia
- Prior art keywords
- protease
- treatment
- neuraminidase inhibitors
- neuropsychiatric disease
- neuropsychiatric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17797100P | 2000-01-25 | 2000-01-25 | |
US60177971 | 2000-01-25 | ||
PCT/US2001/002417 WO2001054729A1 (en) | 2000-01-25 | 2001-01-25 | Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001231137A1 true AU2001231137A1 (en) | 2001-08-07 |
Family
ID=22650670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001231137A Abandoned AU2001231137A1 (en) | 2000-01-25 | 2001-01-25 | Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001231137A1 (en) |
WO (1) | WO2001054729A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0314476D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Compounds |
DE102006036373A1 (en) * | 2006-08-02 | 2008-02-07 | Johannes-Gutenberg-Universität Mainz | Medicament, useful e.g. for the avoidance or alleviation of a poisoning by large clostridial cytotoxins and to combat Clostridium difficile infection, comprises inhibitor or activator of protease activity of clostridial cytotoxin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3026864B2 (en) * | 1991-09-18 | 2000-03-27 | メルシャン株式会社 | New sesquiterpene derivatives |
JP3682977B2 (en) * | 1994-03-25 | 2005-08-17 | グルポ・レペチツト・エス・ピー・エイ | Sesquiterpene derivatives |
EP1043987A4 (en) * | 1998-01-08 | 2004-03-31 | Corporation Thuris | Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host |
JP2002502600A (en) * | 1998-02-06 | 2002-01-29 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Human serine protease and serpin polypeptide |
CA2226919A1 (en) * | 1998-02-13 | 1999-08-13 | Peter Sonderegger | Neuroserpin |
-
2001
- 2001-01-25 AU AU2001231137A patent/AU2001231137A1/en not_active Abandoned
- 2001-01-25 WO PCT/US2001/002417 patent/WO2001054729A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2001054729A1 (en) | 2001-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001249670A1 (en) | Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1 | |
AU2002213357A1 (en) | Variant igg3 rituxan r and therapeutic use thereof | |
AU2003221786A1 (en) | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | |
AU2001259758A1 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
HK1163061A1 (en) | Peptidomimetic protease inhibitors and intermediates for their preparation as treatment for hcv infection | |
IL160295A0 (en) | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | |
PL375052A1 (en) | Pharmaceutical pig and method of use | |
IL157577A0 (en) | Disposable underpants and method of providing the same | |
PL360493A1 (en) | Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus | |
AU2000260550A1 (en) | Treatment of skin damage using polyenylphosphatidylcholine | |
AU1166502A (en) | Human ect2 and methods of use | |
NO20024528L (en) | Protease inhibitor, pharmaceutical composition and use of the compound | |
AU2001294515A1 (en) | Use of stat-6 inhibitors as therapeutic agents | |
AU2001269314A1 (en) | Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds | |
AU2560000A (en) | Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin | |
AU3622600A (en) | Metalloproteinases and methods of use therefor | |
AU2002241661A1 (en) | Multifunctional protease inhibitors and their use in treatment of disease | |
AU2002237667A1 (en) | Methods for the treatment and prevention of urinary stone disease | |
AU6536200A (en) | Proteases and protease inhibitors | |
AU2002337913A1 (en) | Glycosulfopeptide inhibitors and methods of use thereof | |
AU2002346594A1 (en) | Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation | |
AU2002223313A1 (en) | Protease inhibitors and their pharmaceutical uses | |
NO20004920D0 (en) | Use of protease inhibitors for the treatment of skin damage | |
AU2001245414A1 (en) | Treatment of allergies | |
AU2001231137A1 (en) | Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors |